# PERSEE: HCP commentary report

> 217 verified statements (155 from clinicians verified by NPI or staff page) from 73 commentary sources · 10 findings · updated Nov 3, 2026

## Report

- Trial: Randomized, Open-label, Controlled Phase III Trial Comparing Pembrolizumab-platinum Based Chemotherapy Combination With Pembrolizumab Monotherapy in First Line Treatment of Non-small-cell Lung Cancers (NSCLC) With PDL1 Expression ≥50%
- NCT ID: NCT04547504
- Registry: https://clinicaltrials.gov/study/NCT04547504
- Sponsor: University Hospital, Brest
- Phase: Phase 3
- Status: Active, not recruiting
- Drugs tested: pembrolizumab plus platinum-based chemotherapy
- Indication: first-line advanced NSCLC with PD-L1 ≥50%
- Version: v1.0.0, edition 1
- Accepted: 2026-11-03 UTC
- Last checked: 2026-11-03 UTC
- Updated: 2026-11-03 UTC
- Release hash: b29c5611e2c1d874d460f0ab8ec79964524232428196f3e80b56615bbf0d82b7

## Counts

- Commentary sources screened: 129
- Sources cited by verified statements: 76
- Verified statements: 217
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 155
- Findings: 10
- Named people in screened sources (unnamed speakers and accounts not counted): 64
- Voices cited: 64
- Cited voices with a verified identity: 60
- Cited clinicians, voices with a confirmed clinical role (the abstract's clinicians): 44
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 44
- By role and specialty (the abstract's specialty counts):
  - 28 physician, Medical oncology
  - 12 physician
  - 3 physician, Radiation oncology
  - 1 physician, Pathology
- Organisational or shared accounts (not counted as people): 8

A verified identity says who a voice is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified voices without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

PERSEE tested adding chemotherapy to first-line pembrolizumab in PD-L1-high non-small-cell lung cancer; discussion weighs better disease control against unproven survival benefit and substantially greater toxicity. The report cites 44 physicians, including 28 medical oncologists, and contributors described in the sources reviewed for this edition as a PERSEE principal investigator or results authors. Views differ on a chemoimmunotherapy default, with PD-L1-only selection also questioned. Who gains enough early disease control to justify chemotherapy’s burden, who can choose pembrolizumab alone, and how should survival and subgroup uncertainty be explained?

## Open Medical Affairs question

Which patients gain enough early disease control to justify chemotherapy's burden, which can reasonably choose monotherapy, and how should that trade-off be explained without overstating survival or subgroup certainty?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Speakers distinguish better disease control from unproven survival benefit and substantially greater toxicity
- F2. Whether comparator choice, conflicting endpoint accounts and historical benchmarks change interpretation
- F3. Speakers see PERSEE as changing practice but disagree about a chemoimmunotherapy default
- F4. Speakers question PD-L1-only selection and propose clinical or molecular exceptions
- F5. Speakers question whether a negative molecular result adequately excludes a driver
- F6. Speakers disagree over RNA-testing standards, feasibility and educational priorities
- F7. Speakers choose different first-line sequences for a high-PD-L1 never-smoker with CNS disease
- F8. Speakers raise alternative regimens while warning against indirect extrapolation
- F9. Speakers say earlier comparisons did not settle the chemotherapy question
- F10. Speakers praise academic evidence and emphasize patient-centered trade-offs

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 11 | 9 | 9 | 9 | recorded | 2 |
| F2 | 13 | 11 | 6 | 4 | recorded | 3 |
| F3 | 8 | 8 | 6 | 7 | recorded | 2 |
| F4 | 15 | 13 | 8 | 13 | recorded | 3 |
| F5 | 8 | 8 | 1 | 5 | recorded | 2 |
| F6 | 12 | 12 | 1 | 5 | recorded | 2 |
| F7 | 16 | 16 | 2 | 10 | recorded | 2 |
| F8 | 7 | 8 | 3 | 7 | recorded | 3 |
| F9 | 12 | 10 | 8 | 8 | recorded | 3 |
| F10 | 11 | 8 | 8 | 7 | recorded | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 8 | 0 | 1 | 1 | 1 | 11 | 0 | 9 posts and articles | yes |
| F2 | 4 | 3 | 0 | 3 | 3 | 13 | 1 | 4 posts and articles, 2 podcasts and video | yes |
| F3 | 7 | 0 | 0 | 1 | 0 | 8 | 0 | 5 posts and articles, 1 podcast or video | yes |
| F4 | 10 | 5 | 0 | 0 | 0 | 15 | 1 | 8 posts and articles | yes |
| F5 | 7 | 0 | 0 | 0 | 1 | 8 | 0 | 1 post or article | yes |
| F6 | 9 | 2 | 1 | 0 | 0 | 12 | 0 | 1 post or article | yes |
| F7 | 12 | 2 | 1 | 1 | 0 | 16 | 2 | 2 posts and articles | yes |
| F8 | 3 | 2 | 0 | 1 | 1 | 7 | 1 | 3 posts and articles | yes |
| F9 | 10 | 1 | 0 | 1 | 0 | 12 | 1 | 8 posts and articles | yes |
| F10 | 7 | 3 | 0 | 1 | 0 | 11 | 1 | 7 posts and articles, 1 podcast or video | yes |

### Trial dimensions

- Primary endpoint: Progression-free survival (PFS) according to RECIST 1.1 assessed by blinded inependant centra review (BICR): F1 (2 shared claims), F2 (5 shared claims), F3 (1 shared claims), F4 (1 shared claims)
- Secondary endpoints: F1 (7 shared claims), F7 (1 shared claims)
- Population and setting: F3 (3 shared claims), F4 (6 shared claims)
- The comparison: F2 (3 shared claims), F3 (6 shared claims), F10 (1 shared claims)
- Safety and tolerability: F1 (7 shared claims), F4 (1 shared claims), F10 (1 shared claims)
- Design and conduct: F2 (2 shared claims), F3 (1 shared claims)

## Abbreviations

- BICR: blinded independent central review
- CNS: central nervous system
- HCP: healthcare professional
- MCP: Model Context Protocol, how AI agents read the report
- NPI: National Provider Identifier, the US registry number for clinicians
- NSCLC: non-small cell lung cancer
- OS: overall survival
- PD-L1: programmed death-ligand 1
- PFS: progression-free survival
- RECIST: Response Evaluation Criteria in Solid Tumors

## Sample findings

Paraphrased; the full report links each statement to its source.

### F2. Whether comparator choice, conflicting endpoint accounts and historical benchmarks change interpretation

A medical oncologist on X asked whether PERSEE’s follow-up maturity should be considered when selecting a historical pembrolizumab benchmark.

Source: X thread, 2026-10-25.

### F10. Speakers praise academic evidence and emphasize patient-centered trade-offs

In an X thread, a medical oncologist asked about quality-of-life outcomes, subsequent treatments and the scope of subgroup reporting.

Source: X thread, 2026-10-25.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 10 | Titles free |
| Detailed analysis | 11 sections | Paid |
| Verified statements with short source quotes and links | 217 | Paid |
| Who said each statement, with each cited voice's role and what confirmed it (NPI registry or staff page) | 64 | Every edition |
| Trial aspects mapped | 15 | Free |
| Sources with links | 76 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
| Verified speaker IDs as data (NPI, social and scholarly IDs) | 60 | 12-month plan add-on |

Every edition, the free report included, names who said each statement, as the source shows them. Each named voice's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 44 of the 64 cited voices have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key. The verified speaker identities add-on, sold with 12-month plans, adds each verified person's IDs as data (the NPI number, X, Bluesky and LinkedIn accounts, ORCID and institutional pages), so your team can check each attribution itself. It is for checking attribution inside your organization, never for outreach or targeting, and it does not unlock who said what.

## Trial aspects

15 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Progression-free survival (PFS) according to RECIST 1.1 assessed by blinded inependant centra review (BICR) | discussed | 10 | 9 |
| Secondary endpoints | discussed | 12 | 11 |
| Population and setting | discussed | 13 | 9 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 14 | 11 |
| Safety and tolerability | discussed | 12 | 10 |
| Design and conduct | discussed | 10 | 7 |
| Selection beyond PD-L1: fitness, age, burden, comutations and patient preference | discussed | 32 | 18 |
| Conflicting endpoint accounts and historical monotherapy benchmarks | discussed | 12 | 6 |
| Driver exclusion, specimen adequacy and assay blind spots | discussed | 19 | 2 |
| Testing access, RNA standards, costs and peer education | discussed | 19 | 1 |
| Response-adapted treatment and decisions while molecular results are pending | discussed | 20 | 2 |
| Alternative regimens and local versus systemic intensification | discussed | 10 | 6 |
| Earlier comparative evidence and the need for prospective strategy trials | discussed | 17 | 11 |
| Patient priorities, shared decisions and unanswered outcome questions | discussed | 11 | 6 |
| Academic research, practical relevance and treatment intensity over time | discussed | 16 | 14 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 117 | 67 |
| LinkedIn posts | 6 | 4 |
| Bluesky threads | 4 | 0 |
| Podcasts | 1 | 1 |
| YouTube | 1 | 1 |
| Publications (primary source, cited for context) | not screened | 2 |
| Registry (primary source, cited for context) | not screened | 1 |

- Screened window: 2021-01-22 to 2026-11-01
- Cited window: 2021-01-31 to 2026-11-01
- Retrieved: 2026-11-03

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: Randomized, Open-label, Controlled Phase III Trial Comparing Pembrolizumab-platinum Based Chemotherapy Combination With Pembrolizumab Monotherapy in First Line Treatment of Non-small-cell Lung Cancers (NSCLC) With PDL1 Expression ≥50%
- Registry: NCT04547504 (https://clinicaltrials.gov/study/NCT04547504)
- Study IDs: 29BRC20.0159_GFPC01-2020 · GFPC 01-2020 (Groupe Français de Pneumo-Cancérologie)
- Sponsor: University Hospital, Brest
- Collaborators: Groupe Francais De Pneumo-Cancerologie
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Active, not recruiting
- Enrollment: 349 (actual)
- Start: 2020-12-22 (actual)
- Primary completion: 2025-12-22 (estimated)
- Primary endpoint: Progression-free survival (PFS) according to RECIST 1.1 assessed by blinded inependant centra review (BICR) (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months)
- Intervention: Pembrolizumab (drug)
- Intervention: Pembrolizumab and Chemotherapy drugs (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- 1 matching source (1 X thread) could not be read and is not included.
- Not yet captured in this edition: a view on first-line treatment selection, the limited role of added immunotherapy, and concerns about patient selection in prior evidence.
- 2 more clinician views in the sources used in this report are not yet captured as evidence in this edition.
- 182 passages in 80 sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 63 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; 33 sources about other trials or topics are not included.
- The sources reviewed are not a representative sample of all HCPs. Some discussions were not fully assessed, one identified discussion could not be read, and unnamed or differently transcribed references may be absent.
- Several organizational summaries, repeated posts and secondary relays describe the same presentation or publication. Their number cannot be interpreted as the number of independent clinicians endorsing a view.
- The AI-voiced episode does not establish a named clinician as its narrator. “Rafael” is known only by first name in the relevant passage.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- Sources describe some contributors' involvement in PERSEE, but those descriptions are not independent confirmation of trial roles and do not increase the evidentiary weight of their opinions.
- Accounts conflict over primary-endpoint achievement, premature stopping and one interview PFS median. These discrepancies remain visible rather than being silently reconciled.
- OS superiority is not established in the reported comparison; insufficient power and subsequent treatment complicate interpretation but do not prove either benefit or absence of benefit.
- Subgroup, comutation and biomarker interpretations are often exploratory or proposed. Age, histology, sex and molecular features discussed here should not be read as validated treatment-selection rules.
- Earlier indirect comparisons, retrospective analyses, PAULIEN and alternative-regimen discussions retain their own study, setting and timing; they are not PERSEE outcomes.
- Full protocol and regulatory-label text were not available. The report cannot resolve every statistical-plan question or establish label compatibility.
- The available statements do not resolve the requested quality-of-life, detailed molecular, subsequent-treatment or economic questions.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-03 UTC: current edition

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes how the published edition states something, such as a count, a name or a sentence, without making a new edition, so the version stays the same. Every correction is listed here with its date. Last checked for new commentary 2026-11-03 UTC. No corrections.

## Offer

- Size: Standard (217 verified statements)
- Current edition: $1,250. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $2,200
- 6 months of weekly updates: $3,100
- 12 months of weekly updates: $4,400
- Optional verified speaker identities (12-month updates only, product updates-12-identities; speakers are named and described in every report): the NPI and other verified IDs, to check that each statement is attributed to the right person, never for outreach or targeting, at $15 per identity-verified person in the edition at purchase (60 now), at most $1,250; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/persee-nct04547504
- Agents: POST https://www.erudio.com/api/orders with {"report": "persee-nct04547504", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=persee-04547504

## Cite

Erudio Health. PERSEE (NCT04547504): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 3, 2026. https://www.erudio.com/reports/persee-nct04547504

## Machine access

- JSON: https://www.erudio.com/reports/persee-nct04547504.json
- Markdown: https://www.erudio.com/reports/persee-nct04547504.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "persee-nct04547504"}`